Unlock your academic potential and expand your network by joining us!

Journal Article

View at PubMed

Cite as:

ACS Style

Selene Cipri; Ludovico Abenavoli; Luigi Boccuto; Giada Del Baldo; Angela Mastronuzzi. How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care. Medicina 2022, 58, 1386 .

AMA Style

Selene Cipri, Ludovico Abenavoli, Luigi Boccuto, Giada Del Baldo, Angela Mastronuzzi. How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care. Medicina. 2022; 58 (10):1386.

Chicago/Turabian Style

Selene Cipri; Ludovico Abenavoli; Luigi Boccuto; Giada Del Baldo; Angela Mastronuzzi. 2022. "How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care." Medicina 58, no. 10: 1386.


How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care

Medicina

https://doi.org/10.3390/medicina58101386

02 October 2022
1  Department of Hematology/Oncology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children’s Hospital, 00165 Rome, Italy
2  Department of Health Sciences, University Magna Graecia, 88100 Catanzaro, Italy
3  Healthcare Genetics Program, School of Nursing, College of Behavioral, Social and Health Sciences, Clemson University, Clemson, SC 29634, USA

Abstract:

In the last two decades, thanks to the data that have been obtained from the Human Genome Project and the development of next-generation sequencing (NGS) technologies, research in oncology has produced extremely important results in understanding the genomic landscape of pediatric cancers, which are the main cause of death during childhood. NGS has provided significant advances in medicine by detecting germline and somatic driver variants that determine the development and progression of many types of cancers, allowing a distinction between hereditary and non-hereditary cancers, characterizing resistance mechanisms that are also related to alterations of the epigenetic apparatus, and quantifying the mutational burden of tumor cells. A combined approach of next-generation technologies allows us to investigate the numerous molecular features of the cancer cell and the effects of the environment on it, discovering and following the path of personalized therapy to defeat an “ancient” disease that has had victories and defeats. In this paper, we provide an overview of the results that have been obtained in the last decade from genomic studies that were carried out on pediatric cancer and their contribution to the more accurate and faster diagnosis in the stratification of patients and the development of new precision therapies.